Delayed-onset severe neurotoxicity related to blinatumomab in an adolescent patient with refractory acute lymphoblastic leukemia

Pediatr Blood Cancer. 2021 Jul;68(7):e29040. doi: 10.1002/pbc.29040. Epub 2021 Mar 31.

Authors

Maria Filippidou¹, Georgia Avgerinou¹, Katerina Katsibardi¹, Maria Gavra², Roser Pons¹, Antonis Kattamis¹

Affiliations

¹ Division of Pediatric Hematology-Oncology, First Department of Pediatrics, National and Kapodistrian University of Athens, "Aghia Sophia" Children's Hospital, Athens, Greece.
² CT and MRI Department, "Aghia Sophia" Children's Hospital, Athens, Greece.

PMID: 33788389
DOI: 10.1002/pbc.29040

No abstract available

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Antibodies, Bispecific / adverse effects
Antibodies, Bispecific / therapeutic use
Antineoplastic Agents / adverse effects
Humans
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy

Substances

Antibodies, Bispecific
Antineoplastic Agents
blinatumomab